Prevnar 13,the New 13-Valent Pneumococcal Conjugate Vaccine

Abstract

Spanish

French

Objective:

To review the immurtogenicity, efficacy, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in pediatric patients.

Data Sources:

A MEDLINE search (2000-September 2011) was conducted using the key words Streptococcus pneumoniae and pneumococcal conjugate vaccine for clinical trials, limited to studies conducted in humans and published in English.

Studv Selection And Data Extraction:

Randomized, controlled, multicenter trials were reviewed and included to evaluate the safety and efficacy of PCV13, Literature on the epidemiology and pathology of pneumococcal Infections and recommendations from the Advisory Committee on Immunization Practices (ACIP) were also reviewed.

Data Synthesis:

PCV13 is approved for routine vaccination of all infants as a 4-dose series at age 2,4,6, and 12–15 months for children who previously received 1 or more doses of the 7-valent pneumococcal conjugate vaccine (PCV7), and for children with underlying medical conditions that increase their risk for pneumococcal disease or its complications. PCV13 has comparable immunogenicity to the serotypes common with PCV7 and also provides protection against 6 additional pneumococcal serotypes. PCV13 has also been shown to have a comparable adverse reaction profile to PCV7.

Conclusions:

Based on published immunogenicity and safety data, as well as the recent recommendations by the ACIP for routine use in infants and indications for high-risk pediatric patients, PCV13 is a revised formulation of pneumococcal vaccine that should be included on pharmacy formularies.

Keywords

pneumococcal conjugate vaccine Streptococcus pneumoniae

Get full access to this article

View all access options for this article.

References

O'Brien

, Wolfson

, Watt

. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893–902.

Bridy-Pappas

, Margolis

, Center

, Isaacman

. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy 2005; 25:1193–212. DOI 10.1592/phco.2005.25.9.1193

Pilishvili

, Lexau

, Farley

. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32–41. DOI 10.10867648593

Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2010; 59(RR-11): 1–18.

Tyrell

. The changing epidemiology of Streptococcus pneumoniae serotype 19A clonal complexes. J Infect Dis 2011; 203:1345–7. DOI 10.1093/infdis/jir056

Mäkelä

. Conjugate vaccines—a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 2003; 34:249–53.

Product information. Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Philadelphia: Wyeth Pharmaceuticals Inc, a subsidiary of Pfizer Inc., April 2011.

Centers for Disease Control and Prevention. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine—United States, 2007. Morb Mortal Wkly Rep 2010; 59:253–57.

Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126:186–90. DOI 10.1542/peds2010-1280

10.

Dinleyici

, Yargic

. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Exp Rev Vaccines 2009; 8:977–86. DOI 10.1586/ervj09.68

11.

Kaplan

, Barson

, Lin

. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010; 125:429–36. DOI 10.1542/peds.2008-1702

12.

Reinert

, Jacobs

, Kaplan

. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28:4249–59. DOI 10.1016/j.vaccine.2010.04.020

13.

Walker

, Wheeler

, Legg

. Update on the causes, investigation and management of empyema in childhood. Arch Dis Child 2011; 96:482–8. DOI 10.1136/adc.2009.165357

14.

Duggan

. Pneumococcal polysaccharide conjugate vaccine (13-valent adsorbed) [Prevenar 13]. Drugs 2010; 70:1973–86. DOI 0.2165/11205110-000000000-00000

15.

Pai

, Heyneman

, Erramouspe

. Conjugated heptavalent pneumococcal vaccine. Ann Pharmacother 2002; 36:1403–13. DOI 10.1345/aph.1A048

16.

Food and Drug Administration. Prevnar 13: clinical review of biologies license application. Rockville, MD: Food and Drug Administration; 2010. http://wwwida.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM206341.pdf (accessed 2011 May 18).

17.

Jfidar

, Butler

, Carlone

. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 3265–72. DOI 10.1016/S0264-410X(03)00230-5

18.

Romero-Steiner

, Frasch

, Carlone

. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006; 13:165–9. DOI 10.1128/CVI.13.2.165–169.2006

19.

Russell

, Carapetis

, Burton

. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011; 29:535–44. DOI 10.1016/j.vaccine.2010.10.046

20.

Yeh

, Gurtman

, Hurley

. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010; 126:e493–505. DOI 10.1542/peds.2009-3027

21.

Kieninger

, Kueper

, Steul

. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010; 28:4192–203. DOI 10.1016/j.vaccine.2010.04.008

22.

Bryant

, Block

, Baker

. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125: 866–75. DOI 10.1542/peds.2009-1405

23.

Esposito

, Tansey

, Thompson

. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17:1017–26. DOI 10.1128/CVI.00062-10

24.

Snape

, Klinger

, Daniels

. Immunogenicity and reactogenicity of a 13-valent-pneumococcaI conjugate vaccine administered at 2,4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010; 29:e80–90. DOI 10.1097/INF.0b013e3181faa6be

25.

Centers for Disease Control and Prevention. General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2011; 60(2):1–64.

26.

Nahata

, Taketomo

. Pediatrics. In: DiPiro

, Talbert

, Yee

, eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill, 2008: 47.

27.

Centers for Disease Control and Prevention. Vaccine information statements. http://www.cdc.gov/vaccines/pubs/vis/default.htm (accessed 2011 May 11).

28.

Rubin

, McGarry

, Strutton

. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 201028:7634–43. DOI 10.1016/j.vaccine.2010.09.049

29.

Chuck

, Jacobs

, Tyrrell

. Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines. Vaccine 2010; 28:5485–90. DOI 10.1016/j.vaccine.2010.05.058

30.

Product inormation. Synflorix (pneumococcal 10-valent conjugate vaccine). Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; 2009.

31.

Rozenbaum

, Sanders

, van Hoek

. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010; 340:c2509. DOI 10.1136/bmj.c2509

32.

Paradiso

. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011; 52:1241–7. DOI 10.1093/cid/cir142

33.

Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 0 through 6 years—United States, 2011. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/0-6yrs-schedule-pr.pdf (accessed 2011 Aug 1).

34.

Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 7 through 18 years—United States, 2011. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/7-18yrs-schedule-bw.pdf (accessed 2011 Aug 1).

35.

Techasaensiri

, Messina

, Katz

. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J 2010; 29:294–300. DOI 10.1097/INF.0b013e3181c2a229